Ieramilimab
id:
ieramilimab-253-895379
title:
Ieramilimab
text:
Ieramilimab is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that 'dosing is imminent' for the first clinical trials of LAG525. Ieramilimab's first clinical trial is a Phase I in patients with various solid tumors, in combination with spartalizumab (PDR001), an anti-PD-1 monoclonal
brand slug:
wiki
category slug:
encyclopedia
description:
original url:
https://en.wikipedia.org/wiki/Ieramilimab
date created:
date modified:
2023-02-07T19:04:03Z
main entity:
{"identifier":"Q25111469","url":"https://www.wikidata.org/entity/Q25111469"}
image:
fields total:
13
integrity:
13